epilepsy
Conditions
Interventions
Levetiracetam sustained-release granules treatment group:None
Sponsors
Shanghai General Hospital
Eligibility
Sex/Gender
All
Age
12 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Diagnosed with focal epilepsy in accordance with the classification and diagnostic criteria of the International League Against Epilepsy (ILAE), 2025; 2.Patients were treated with at least one antiseizure medication (ASM) before enrollment, with no levetiracetam contained in the current treatment regimen. Add-on treatment with levetiracetam sustained-release granules was required as judged by the attending physician; 3.All participants provided written informed consent (signed by legal guardians for minor patients); 4. Age >= 12 years old;
Exclusion criteria
Exclusion criteria: 1.Pregnant or lactating women; 2.Patients with hypersensitivity to levetiracetam sustained-release granules or their excipients; 3.Patients with other severe comorbidities requiring priority treatment; 4.Other patients deemed ineligible for this study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The 6-month response rate in patients treated with levetiracetam sustained-release granules; | — |
Secondary
| Measure | Time frame |
|---|---|
| The retention rates of levetiracetam sustained-release granules at 3 and 6 months of treatment;The seizure-free rate at 6 months of treatment with levetiracetam sustained-release granules, defined as the proportion of patients who achieved seizure-free status during LEV SR therapy;The seizure-free and response rates at 3 months of treatment with levetiracetam sustained-release granules; | — |
Countries
China
Contacts
Public ContactWu Yuncheng
Shanghai General Hospital
Outcome results
None listed